Publication / Source: Neurology Central
Authors: David Howett
Dr Mormino and colleagues at Massachusetts General Hospital (USA) have developed a composite genetic risk score that is associated with a host of Alzheimer’s disease (AD) biomarkers, but what does this mean for treatment? As reported earlier this month, common polygenic risk scores (PgRS) were increased in individuals without dementia and present in individuals as young as 18.
“The goal of this type of research is to help physicians better identify those at high risk of dementia so that future preventative treatments may be used as early as possible” commented Mormino in a press release from Neurology.
This article reflects the demand for earlier identification and characterization of predementia AD, representing one of the largest priorities for health services in developed countries. Given that evidence suggests that underlying AD pathophysiology is apparent 10 years prior to symptom onset, the successful identification of preclinical AD will improve clinical management and represents the optimal point of intervention for prospective clinical trials.